TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

How is the definition of high-risk MM evolving?

Featured:

Bruno PaivaBruno Paiva

May 20, 2022


During the 3rd European Myeloma Network Meeting, the Multiple Myeloma hub was pleased to speak to Bruno Paiva, University of Navarra, Pamplona, ES. We asked, How is the definition of high-risk multiple myeloma (MM) evolving?

How is the definition of high-risk MM evolving?

Paiva begins by explaining how the evolution of defining high-risk MM has been positive over the past few decades, which could lead to significant improvements in how patients are staged in the future. The starting point for defining high-risk MM is a Revised International Staging System (R-ISS) Stage 3. Paiva states that this is effective; however, there is room for improvement, either by increasing the accuracy of risk stratification at baseline or after treatment, for example by assessing additional cytogenetic abnormalities, analyzing tumor burden, and evaluating minimal residual disease.